Abstract
Introduction
Clinical remission in severe asthma has been poorly studied and remains to be defined.
Aims and Objectives
We explored factors associated with different definitions of asthma remission at ~1-year post-biologic
initiation.
Methods
Using data from the International Severe Asthma Registry (ISAR) in 1347 patients who initiated their first
biologics, we a priori defined four composite definitions of remission: 1) no exacerbation and no long-term
oral corticosteroid (LTOCS) use; 2) plus partly/well controlled asthma; 3) or percent predicted FEV1 ≥80%;
and 4) all criteria combined. We examined the association between different definitions of remission and
selected patient’s characteristics (Figure 1) using logistic regressions.
Results
Fewer exacerbations, lower LTOCS use, better symptom control, and better lung function prior to biologic
initiation were positively associated with remission, regardless of the definition applied. Odds of remission
were also higher in patients with lower body mass index, shorter asthma duration, and T2-related
comorbidities (Figure 1). For example, a 10-year increment in asthma duration was associated with a 19%
reduction (p=.015) of remission odds (all criteria combined).
Conclusions
Initiating biologics earlier in the disease history, before the development of severe impairments, is
associated with an increased likelihood of clinical remission following biologic initiation
Clinical remission in severe asthma has been poorly studied and remains to be defined.
Aims and Objectives
We explored factors associated with different definitions of asthma remission at ~1-year post-biologic
initiation.
Methods
Using data from the International Severe Asthma Registry (ISAR) in 1347 patients who initiated their first
biologics, we a priori defined four composite definitions of remission: 1) no exacerbation and no long-term
oral corticosteroid (LTOCS) use; 2) plus partly/well controlled asthma; 3) or percent predicted FEV1 ≥80%;
and 4) all criteria combined. We examined the association between different definitions of remission and
selected patient’s characteristics (Figure 1) using logistic regressions.
Results
Fewer exacerbations, lower LTOCS use, better symptom control, and better lung function prior to biologic
initiation were positively associated with remission, regardless of the definition applied. Odds of remission
were also higher in patients with lower body mass index, shorter asthma duration, and T2-related
comorbidities (Figure 1). For example, a 10-year increment in asthma duration was associated with a 19%
reduction (p=.015) of remission odds (all criteria combined).
Conclusions
Initiating biologics earlier in the disease history, before the development of severe impairments, is
associated with an increased likelihood of clinical remission following biologic initiation
| Original language | English |
|---|---|
| Publication status | Published - 15 Jun 2023 |
| Event | ERS 2023 International Congress - Duration: 7 Sept 2023 → 13 Sept 2023 https://www.ersnet.org/congress-and-events/congress/ |
Conference
| Conference | ERS 2023 International Congress |
|---|---|
| Period | 7/09/23 → 13/09/23 |
| Internet address |